Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04404777
Active, not recruiting Observational

Local Recurrence Due to Rectal Cancer in Sweden

NCT04404777 · tracked via the Priya Life Science Sweden tracker
Sponsor
Sahlgrenska University Hospital
Phase
Observational
Started
2022-07-01
Last updated
2025-06-17

Condition(s) studied

Rectal Neoplasms

Investigational drug(s) / intervention(s)

Treatment for local recurrence with surgery or other treatments

Treatment for local recurrence with surgery or other treatments: All types of treatment for local recurrence will be evaluated

Study summary

The aim of this retrospective national registry study is to validate the reporting of local recurrence in the registry. Another aim is to identify preoperative risk factors for local recurrence. This can in turn indicate the need for a more intense follow-up. The treatment of local recurrence, including the impact of the multidisciplinary team conference (MDT) and the surgical procedure and the referral pathways of local recurrences will also be determined.

We aim to evaluate treatment outcome after local recurrence for patients operated or treated between 2007-2018.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Rectal cancer with a curative intent Exclusion Criteria: * Rectal cancer without curative intent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dept. of Surgery, Sahlgrenska University Hospital/Ostra Gothenburg Sweden

More Sahlgrenska University Hospital trials in Sweden

Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma Recruiting
Placebo Effect In Spinal Cord Electrical Stimulation for Pain Recruiting
Incidence, Treatment and Outcome After Acute Mesenteric Ischemia in the Region of Västra Götaland, 2000-2023. Active, not recruiting
Watch and Wait as Treatment for Patients With Rectal Cancer Recruiting
Predicting Colorectal Cancer - Tissue Samples to Evaluate Tumour Characteristics and Treatment Response Recruiting

Other trials for the same condition

Watch and Wait as Treatment for Patients With Rectal Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04404777 on ClinicalTrials.gov ↗ ← All trials in Sweden